Guest guest Posted July 29, 2005 Report Share Posted July 29, 2005 http://www.nytimes.com/2005/07/26/science/26conv.html Some excerpts: ..................... Dr. McKerrow, 57, a pathologist and biochemist, lives out his family's traditions in the way he does his science. As the director of the Sandler Center for Basic Research in Parasitic Diseases at the University of California, San Francisco, he has been looking for - and finding - promising new treatments for parasitic infections that sicken millions of people in the developing world. .................. At my lab, we are working on the five neglected diseases of mankind - malaria; schistosomiasis; leishmaniasis, a k a the Baghdad boil; African sleeping sickness; and Chagas' disease. .................... Q. How does a researcher get past a roadblock like the lack of interest of pharmaceutical companies? A. At my lab, we've been circumventing the problem by becoming a kind of pharmaceutical company ourselves. With funding from the Sandler Family Foundation, we've purchased machines that facilitate new styles of research. There's this new computerized robot that permits a researcher to quickly assay thousands of substances to see if they might be effective against parasites. In the past, if you wanted to test 1,000 compounds, you'd need 1,000 scientists pouring chemicals between test tubes, back and forth, back and forth. With this new technology, you can test 1,000 substances in a couple of hours. After we got the machine, we ran " libraries " of F.D.A.-approved drugs for other uses through it. Very quickly, we've found 90 with promise as antiparasitic agents. The big thing is, we've quickly found something that might combat African sleeping sickness. Q. What kinds of drugs did you test? A. We tried Cialis, but it wasn't a hit. For African sleeping sickness, we got hits for a well-known antidepressant, a muscle relaxant, an antibiotic and " old man's beard, " a plant compound sometimes used in traditional Chinese medicine. The muscle relaxant and the anti-depressant are particularly promising because they bypass the blood-brain barrier, a requirement in this neurological disease. Since these drugs are approved for other uses, it shortcuts the process of getting them out there. Of course, they'll have to be tested on infected people. By the way, we've had good luck on Chagas' disease, too - though we tried something different there. We actually have a drug candidate that has already successfully passed animal testing and will soon be ready to be tested on people.e ............... Sue , Upstate New York Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.